PowerVision develops the FluidVision™ fluid-based accommodating intraocular lens intended to restore clear vision at all distances for patients with cataracts and presbyopia. The lens mimics the eye’s natural accommodative process by changing shape to adjust focus, and is implanted using the same surgical techniques as traditional intraocular lenses. The company is led by Barry Cheskin, President & CEO and Co‑Founder. PowerVision intends to use new funds to complete patient enrollment in its ongoing CE Mark study, with enrollment expected to be completed by the end of the year. The company expects receipt of the CE mark and the subsequent launch of a U.S. pivotal study in 2015. No operating metrics were disclosed in the article. PowerVision develops an accommodating intraocular lens that uses fluids inside the lens combined with the eye’s natural muscle forces to change shape and restore accommodative function. The company says its technology has the potential to create an average of five or more diopters of power change, approximating the accommodative range of a 35‑year‑old. Implants of intraocular lenses in the U.S. exceed three million each year, and PowerVision believes its product could restore spectacle independence for millions of patients. PowerVision is pursuing clinical development and regulatory approval; its products are not yet approved or cleared for sale. The company is funding ongoing R&D and a clinical trial targeted at achieving the CE Mark in Europe. The company is a private entity operating from Belmont, Calif. PowerVision is a Belmont, Calif.-based medical device company developing implantable intraocular lenses. Its product is a fluid-controlled lens designed to treat presbyopia by responding to natural muscular forces in the eye, shifting liquid to alter lens shape and focus. The company's website appeared offline at the time of reporting. PowerVision raised $20 million in a second funding round from Advanced Technology Ventures, Frazier Healthcare Ventures and J.P. Morgan Partners. The new funding was expected to carry the company about one-third of the way through clinical trials, which it anticipated beginning in late 2008 or early 2009. PowerVision previously raised $9 million in late 2004.

Total raised

$87M

Funding rounds

3

Latest round

Series D

Latest activity

Jun 2014